Kenneth C Childers
Overview
Explore the profile of Kenneth C Childers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Avery N, Childers K, McCarty J, Spiegel P
J Phys Chem B
. 2025 Jan;
129(5):1486-1498.
PMID: 39840640
During the blood coagulation cascade, coagulation factor VIII (FVIII) is activated by thrombin to form activated factor VIII (FVIIIa). FVIIIa associates with platelet surfaces at the site of vascular damage...
2.
Avery N, Young I, Lu S, Vaughan J, Korus P, Richardson T, et al.
J Thromb Haemost
. 2024 Nov;
23(2):513-524.
PMID: 39549835
Background: Following proteolytic activation, activated blood coagulation factor (F)VIII (FVIIIa) binds to activated platelet membranes, forming the intrinsic tenase complex with activated FIX (FIXa). Previous studies have identified the C1...
3.
Childers K, Cowper B, Vaughan J, McGill J, Davulcu O, Lollar P, et al.
J Thromb Haemost
. 2024 Jun;
22(9):2449-2459.
PMID: 38849084
Background: Hemophilia A arises from dysfunctional or deficient coagulation factor (F)VIII and leads to inefficient fibrin clot formation and uncontrolled bleeding events. The development of antibody inhibitors is a clinical...
4.
Coyle C, Knight K, Brown H, George S, Denning G, Branella G, et al.
J Thromb Haemost
. 2023 Nov;
22(3):633-644.
PMID: 38016519
Background: Laboratory resurrection of ancient coagulation factor (F) IX variants generated through ancestral sequence reconstruction led to the discovery of a FIX variant, designated An96, which possesses enhanced specific activity...
5.
Childers K, Avery N, Estrada Alamo K, Davulcu O, Haynes R, Lollar P, et al.
Blood
. 2023 May;
142(2):197-201.
PMID: 37192299
The development of pathogenic antibody inhibitors against coagulation factor VIII (FVIII) occurs in ∼30% of patients with congenital hemophilia A receiving FVIII replacement therapy, as well as in all cases...
6.
Peters S, Childers K, Mitchell C, Avery N, Reese Jr S, Mitchell C, et al.
Front Mol Biosci
. 2022 Nov;
9:1040106.
PMID: 36387287
At sites of vascular damage, factor VIII (fVIII) is proteolytically activated by thrombin and binds to activated platelet surfaces with activated factor IX (fIXa) to form the intrinsic "tenase" complex....
7.
Childers K, Peters S, Spiegel Jr P
J Thromb Haemost
. 2022 Jun;
20(9):1957-1970.
PMID: 35722946
Advances in structural studies of blood coagulation factor VIII (FVIII) have provided unique insight into FVIII biochemistry. Atomic detail models of the B domain-deleted FVIII structure alone and in complex...
8.
Childers K, Peters S, Lollar P, Spencer H, Doering C, Spiegel P
Blood Adv
. 2022 Mar;
6(11):3240-3254.
PMID: 35255502
The intrinsic tenase (Xase) complex, formed by factors (f) VIIIa and fIXa, forms on activated platelet surfaces and catalyzes the activation of factor X to Xa, stimulating thrombin production in...
9.
Ronayne E, Peters S, Gish J, Wilson C, Spencer H, Doering C, et al.
Front Immunol
. 2021 Jun;
12:697602.
PMID: 34177966
Factor VIII (fVIII) is a procoagulant protein that binds to activated factor IX (fIXa) on platelet surfaces to form the intrinsic tenase complex. Due to the high immunogenicity of fVIII,...
10.
Gish J, Jarvis L, Childers K, Peters S, Garrels C, Smith I, et al.
Blood
. 2021 Feb;
137(21):2981-2986.
PMID: 33529335
Antibody inhibitor development in hemophilia A represents the most significant complication resulting from factor VIII (fVIII) replacement therapy. Recent studies have demonstrated that epitopes present in the C1 domain contribute...